Late-Breaking Abstract on AV Access Trial to Be Presented at Kidney Week

Mohamad A. Hussain, MD, PhD, RPVI, FAHA, FRCSC, FACS, of Brigham and Women’s Hospital and Harvard Medical School will present a late-breaking oral abstract at the American Society of Nephrology Kidney Week in San Diego, California, on October 26.

“Prospective Randomized Trial of Humacyte’s Acellular Tissue Engineered Vessel Versus Autologous Arteriovenous Fistula for Hemodialysis Access” will report on the V007 phase 3 clinical trial of the acellular tissue engineered vessel (ATEV) in arteriovenous access for patients with end-stage renal disease.

Humacyte is a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale. Its initial product candidates, a portfolio of ATEVs, are in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease.

Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive Regenerative Medicine Advanced Therapy designation from the US Food and Drug Administration (FDA), and it has also received FDA Fast Track designation.

The company plans to provide additional details from the oral presentation in a future press release.